The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer.
The main questions it aims to answer are:
1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.
Performance status (ECOG PS) 0-2
Diagnosed with metastatic disease
Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)
Patient with a history of prior radiotherapy to the site planned for SABR
Patients with concomitant brain metastases
Cancer patients who are Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)
Cohort
Prospective
Stereotactic body radiotherapy (SBRT)
RadiationStereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).
Progression-free survival
Time from the start of stereotactic body radiotherapy (SABR) to the first documented event of local failure, distant failure, death from any cause, or last follow-up, whichever occurs first.
Physician assessed toxicity
Evaluated by treating physician based on CTCAE ver 5.0
Patient-reported outcome
It will be measured by PRO-CTCAE coreset 12.
Local failure
Local regrowth or progression at the site of SABR.
Click on the lead sponsor to view all of their trials.
